Tiemann Investment Advisors LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 4.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,870 shares of the company’s stock after selling 814 shares during the period. Johnson & Johnson comprises approximately 1.9% of Tiemann Investment Advisors LLC’s portfolio, making the stock its 6th largest position. Tiemann Investment Advisors LLC’s holdings in Johnson & Johnson were worth $2,628,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in JNJ. Thoroughbred Financial Services LLC boosted its holdings in shares of Johnson & Johnson by 14,147.0% during the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after purchasing an additional 3,986,071 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Johnson & Johnson by 145.5% during the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock worth $604,637,000 after purchasing an additional 2,572,695 shares during the period. APG Asset Management N.V. boosted its holdings in shares of Johnson & Johnson by 61.4% during the second quarter. APG Asset Management N.V. now owns 5,188,736 shares of the company’s stock worth $634,604,000 after purchasing an additional 1,973,700 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Johnson & Johnson by 14.2% during the first quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after purchasing an additional 1,079,751 shares during the period. Finally, Mn Services Vermogensbeheer B.V. boosted its holdings in shares of Johnson & Johnson by 152.1% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 1,083,996 shares of the company’s stock worth $122,372,000 after purchasing an additional 654,085 shares during the period. Institutional investors own 72.01% of the company’s stock.

JNJ has been the subject of a number of analyst reports. Barclays initiated coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Bank of America reiterated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Finally, Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $150.60.

JNJ stock traded down $0.98 during trading on Monday, reaching $129.80. The company had a trading volume of 2,235,344 shares, compared to its average volume of 7,524,661. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The company has a market cap of $344.23 billion, a P/E ratio of 15.87, a PEG ratio of 2.21 and a beta of 0.68. The business has a 50 day moving average of $130.14 and a 200 day moving average of $135.94. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the prior year, the firm earned $2.10 earnings per share. Johnson & Johnson’s revenue was down 1.3% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: How is Preferred Stock Different from Common Stock?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.